GSE69836
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK-positive cell growth.
We used bisulfite conversion and Illumina sequencing to analyse miR-150 DNA methylation pattern lost in cells treated with decitabine, a demethylating agent, Crizotinib, an inhibitor of  of ALK activity or siALK Overall design: Targeted bisulfite conversion and Illumina sequencing in two cell lines bearing the t(2;5)(p23;q35)